TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15007374
Drug: Lidocaine instillation
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine instillation enhanced by electromotive drug administration (EMDA)
Study: 9893772
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous antibiotic therapy with cefamandole 1 g i.v. every 6 h for 7 days
Study: 9893772
Drug: Abbreviated intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abbreviated intravenous therapy with cefamandole (1 g i.v. every 6 h for 2 days) followed by oral therapy with cefaclor (500 mg every 8 h for 5 days)
Study: 8031068
Drug: Antacids in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacids in didanosine tablets
Study: 8031068
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of 300 mg isoniazid
Study: 2544345
Drug: Naloxone (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (all doses)
Study: 25894531
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of 400 μg of salbutamol
Study: 17346304
Drug: Venlafaxine XR
Normalized name: venlafaxine Extended Release Oral Capsule
DrugBank: Venlafaxine (DB00285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Venlafaxine XR (150 mg/day), n = 34
Study: 12016602
Drug: 5.0 mg
Normalized name: RUXOLITINIB 5.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg hyperbaric bupivacaine
Study: 2007107
Drug: 7.5 mg
Normalized name: biotin 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg hyperbaric bupivacaine
Study: 12016602
Drug: 10.0 mg
Normalized name: RUXOLITINIB 10.0 mg ORAL TABLET [JAKAFI]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.0 mg hyperbaric bupivacaine
Study: 12016602
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg hyperbaric bupivacaine
Study: 10440603
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg three times daily
Study: 10440603
Drug: Lansoprazole 15
Normalized name: lansoprazole 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 15 mg twice daily
Study: 16431305
Drug: Lansoprazole 30
Normalized name: lansoprazole 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lansoprazole 30 mg twice daily
Study: 2186587
Drug: Single infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single infusion of 8 g fosfomycin and 1 g metronidazole at induction of anaesthesia (Group 1)
Study: 2186587
Drug: Bacitracin 250
Normalized name: Bacitracin 250 unit/g and neomycin sulfate 5 mg/g and sulfacetamide sodium 60 mg/g cutaneous powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacitracin 250 mg plus neomycin 250 mg (as four tablets on three occasions over two days), metronidazole 500 mg tablets three times a day for one day, and ampicillin 1 g intravenously at induction of anaesthesia (Group 2)
Study: 6243242
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy (cyclophosphamide, methotrexate, vincristine) and radiation therapy
Study: 6243242
Drug: Cyclophosphamide and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide and radiation therapy
Study: 24187863
Drug: Jianjining granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jianjining granules and Western Medicine (prednisone or pyridostigmine bromide)
Study: 17824291
Drug: Eprosartan (477.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (477.5 +/- 143.7 mg/d)
Study: 17824291
Drug: Telmisartan (65.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan (65.9 +/- 17.7 mg)
Study: 17824291
Drug: Candesartan (11.9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (11.9 +/- 4.0 mg)
Study: 17824291
Drug: No sartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: No sartan treatment (Control group)
Study: 15232456
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa (two-dose regime)
Study: 11686355
Drug: Once-daily low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily low molecular weight heparin
Study: 11686355
Drug: Twice-daily low
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily low molecular weight heparin
Study: 9645829
Drug: Chlorthalidone (12.5-25.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5-25.0 mg/d) with the addition of atenolol (25-50 mg/d) or reserpine (0.05-0.10 mg/d) if needed
Study: 9645829
Drug: Chlorthalidone (12.5-25.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5-25.0 mg/d)
Study: 24919887
Drug: 75 μg of
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 μg of desogestrel/die for 5 weeks
Study: 24919887
Drug: 100 mg of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of danazol/die for 5 weeks
Study: 15998708
Drug: Powdered North
Normalized name: North American coral snake antivenin
DrugBank: Coral snake (micrurus fulvius) immune globulin antivenin (equine) (DB13883)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Powdered North American ginseng (3 g)
Study: 7735418
Drug: Nebulized salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nebulized salbutamol (0.15 mg/kg per dose)
Study: 1675029
Drug: 100 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micrograms of purified gonococcal pilus vaccine given intradermally on day 1 and day 14
Study: 24602167
Drug: Non-restorative caries
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-restorative caries treatment (NRCT)
Study: 21457202
Drug: Adalimumab 80
Normalized name: ADALIMUMAB 80MG/0.8ML INJ PEN KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80 mg subcutaneously at baseline followed by 40 mg every other week for 12 weeks
Study: 21457202
Drug: Placebo (identical-looking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical-looking injections with no active ingredient)
Study: 16843806
Drug: Nonabsorbable suture
Normalized name: COLLAGEN HEMOSTAT,ABSORBABLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonabsorbable suture anchor (G II, DePuy Mitek)
Study: 12969091
Drug: High-dose therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 500 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Study: 12969091
Drug: Low-dose therapy
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose therapy (rabeprazole 20 mg b.d., amoxicillin 1 g b.d. for 5 days, followed by rabeprazole 20 mg b.d., clarithromycin 250 mg b.d., and tinidazole 500 mg b.d. for 5 days)
Study: 8406151
Drug: SMS 201‐995
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMS 201‐995 (25 micrograms subcutaneously three times daily)
Study: 8406151
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg once a day)
Study: 8406151
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy of SMS 201‐995 and omeprazole
Study: 3530612
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 20 m‐units min‐1 m‐2
Study: 3530612
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 80 m‐units min‐1 m‐2
Study: 3530612
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at 200 m‐units min‐1 m‐2
Study: 3530612
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at all three rates
Study: 3530612
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion at all three doses
Study: 27173100
Drug: Tecarfarin (CYP2C9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tecarfarin (CYP2C9 interacting drugs)
Study: 27173100
Drug: Warfarin (CYP2C9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (CYP2C9 interacting drugs)
Study: 27173100
Drug: Warfarin (mechanical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (mechanical heart valves)
Study: 27173100
Drug: Warfarin (CYP2C9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (CYP2C9 variant allele)
Study: 24997182
Drug: sham injections
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham injections
Study: 15753241
Drug: 0.25 mg
Normalized name: biotin 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg lorazepam
Study: 12767566
Drug: Lycopene (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene (2 mg twice daily)
Study: 8892714
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of NA and 1 microg of EE2
Study: 8892714
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg of NA and 2.5 microg of EE2
Study: 8892714
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of NA and 5 microg of EE2
Study: 8892714
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg of NA and 10 microg of EE2
Study: 8892714
Drug: NA-EE2 treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: NA-EE2 treatments
Study: 1676825
Drug: British group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: British group (unrestricted prescribing of H2-receptor antagonists)
Study: 1676825
Drug: Australian group
Normalized name: Australian pine pollen extract
DrugBank: Casuarina equisetifolia pollen (DB10485)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Australian group (H2-receptor antagonists allowed only after gastroscopy or barium meal)
Study: 21636735
Drug: Exercise +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise + Supplement (E + S) with 70 g of honey
Study: 21636735
Drug: Exercise (E)
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exercise (E) with 70 g of artificial sweetener
Study: 17331388
Drug: Tulobuterol tablet
Normalized name: tulobuterol
DrugBank: Tulobuterol (DB12248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tulobuterol tablet
Study: 2620671
Drug: Ciprofloxacin 500
Normalized name: ciprofloxacin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 500 mg p.o. (n = 21)
Study: 2620671
Drug: Ciprofloxacin 200
Normalized name: ciprofloxacin 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ciprofloxacin 200 mg i.v. over 30 min (n = 15)
Study: 29687650
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss plus whey protein supplementation (total protein: 1.2 g/kg/d)
Study: 29687650
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss and the recommended daily allowance for protein (0.8 g/kg/d)
Study: 20185805
Drug: Anemic residents
Normalized name: IRON 100 mg in 1 mL INTRAMUSCULAR INJECTION [ANEM-X 100]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anemic residents treated with at least one medication
Study: 18206569
Drug: Tai Chi
Normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tai Chi Chuan (TCC) exercises; specific dosage and duration not mentioned.
Study: 11121996
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg, 50 mg, 100 mg)
Study: 9772138
Drug: High-energy supplement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy supplement (HES) 2.14 MJ/d
Study: 9772138
Drug: Low-energy supplement
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy supplement (LES) 0.50 MJ/d
Study: 9772138
Drug: High-energy supplement
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy supplement (HES)
Study: 9772138
Drug: Low-energy supplement
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy supplement (LES)
Study: 7876659
Drug: Contrast echocardiography
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contrast echocardiography with 200 mg/ml and 400 mg/ml SHU 508A intravenously
Study: 3207375
Drug: Intravenous pulsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous pulsed methylprednisolone
Study: 1105833
Drug: Neomycin-erythromycin combination
Normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Neomycin-erythromycin combination (3 gm of each, day preoperatively, plus mechanical cleansing)
Study: 1105833
Drug: Other preparations
Normalized name: other preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other preparations
Study: 28081990
Drug: Standard volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard volume local anesthetic administered (Group S, n=30)
Study: 28081990
Drug: Low volume
Normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low volume anesthetic administered (Group L, n=30)
Study: 28081990
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Group L and Group S)
Study: 11445475
Drug: Anterior vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anterior vaginal wall suspension for urethral hypermobility (UH group)
Study: 9860150
Drug: L-NAME 1
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME 1 mg x kg(‐1) x h(‐1) for 12 hours
Study: 3051839
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TS) adhesive, delivering 140 micrograms initially and 5 micrograms/h thereafter
Study: 3051839
Drug: Droperidol (DHBP)
Normalized name: Droperidol
DrugBank: Droperidol (DB00450)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Droperidol (DHBP) 0.5 ml (1.25 mg) i.v.
Study: 3051839
Drug: Placebo (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.5 ml i.v.)
Study: 8919900
Drug: Transdermal scopolamine
Normalized name: Transderm Scop
DrugBank: Scopolamine (DB00747)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal scopolamine (TS)
Study: 28634136
Drug: Pinaverium (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium (50 mg tablets, 3 times daily for 4 weeks)
Study: 23144445
Drug: Cindunistat 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cindunistat 50 mg/day
Study: 23144445
Drug: Cindunistat 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cindunistat 200 mg/day
Study: 23144445
Drug: Cindunistat (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cindunistat (50 or 200 mg/day)
Study: 16945898
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri ATCC 55730 via straw (200 ml of water through a prepared straw once daily for 3 weeks)
Study: 16945898
Drug: Lactobacillus reuteri
Normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus reuteri ATCC 55730 via tablet (one tablet once daily for 3 weeks)
Study: 16945898
Drug: Placebo straw
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo straw (200 ml of water through a placebo straw once daily for 3 weeks)
Study: 16945898
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet (one placebo tablet once daily for 3 weeks)
Study: 14705152
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus nutritional supplements
Study: 14705152
Drug: Fluoxetine plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine plus nutritional placebo
Study: 8204245
Drug: Nicardipine 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicardipine 1 mg
Study: 3294914
Drug: Listerine mouthrinse
Normalized name: Listerine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine mouthrinse (20 ml for 30 s, twice daily)
Study: 3294914
Drug: Chlorhexidine mouthrinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorhexidine mouthrinse (0.2% or 0.1% solution, 10 ml for 60 s, twice daily)
Study: 3294914
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (20 ml mouthrinse for 30 s, twice daily)
Study: 25476072
Drug: Outreach-based treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outreach-based treatment
Study: 20207664
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects related to smoking cessation
Study: 20207664
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects related to diet
Study: 20207664
Drug: Treatment effects
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment effects related to sun exposure
Study: 2149051
Drug: Ciprofloxacin (monotherapy)
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ciprofloxacin (monotherapy)
Study: 16995327
Drug: Metoprolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (50 mg)
Study: 28534225
Drug: Controlled dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled dietary acrylamide intake via coffee (0.15-0.17 µg/kg bw) and a meal (14.1-15.9 µg/kg bw) on days 6 and 10 respectively.
Study: 28534225
Drug: Controlled dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Controlled dietary acrylamide minimized diet (0.05-0.06 µg/kg bw) throughout the 13-day study period.
Study: 28534225
Drug: Ingestion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ingestion of 13C3D3-AA (1 µg/kg bw) on day 6.
Study: 25400681
Drug: Vitamin D3
Normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D3 2000 IU once daily
Study: 8080348
Drug: Yohimbine hydrochloride,
Normalized name: Yohimbine Hydrochloride, 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine hydrochloride, 0.4 mg/kg
Study: 10613225
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human erythropoietin (rHuEPO), 6000 U i.v. twice weekly for 3 weeks
Study: 7261552
Drug: Propranolol (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (80 mg b.i.d.)
Study: 29153938
Drug: Tribendimidine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribendimidine (200 mg for children, 400 mg for adolescents and adults)
Study: 29153938
Drug: Praziquantel (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (50 mg/kg bodyweight and 25 mg/kg bodyweight, 6 h apart)
Study: 26768923
Drug: Nitrous oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrous oxide (N2O) 65% in oxygen (O2) via mask, flow of 10 L/min
Study: 26768923
Drug: Oxygen (O2)
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxygen (O2) only, flow of 10 L/min (control group)
Study: 15389231
Drug: Ezetimibe (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ezetimibe (10 mg/day) plus atorvastatin (10 mg/day, titrated to 40 mg/day if needed)
Study: 15389231
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg/day, titrated to 80 mg/day if needed)
Study: 7722120
Drug: Candoxatrilat 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candoxatrilat 200 mg
Study: 2024791
Drug: Metaproterenol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metaproterenol (15 mg by nebulizer)
Study: 2024791
Drug: Atropine (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine (1.5 mg by nebulizer)
Study: 24824633
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg twice a day
Study: 17571092
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment deferred to normal waiting list, received three home visits)
Study: 15519028
Drug: Caffeine (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (200 mg, equivalent to 2 cups of coffee)
Study: 1771604
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (800 micrograms twice daily)
Study: 30771791
Drug: Mitochondrial agents,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mitochondrial agents, N-acetylcysteine
Study: 26396135
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of ALC hydrochloride 590 mg
Study: 26396135
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of ALC hydrochloride 590 mg
Study: 11444885
Drug: Subcutaneous carbon-dioxide
Normalized name: Carbon Dioxide
DrugBank: Carbon dioxide (DB09157)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous carbon-dioxide insufflations (10 treatments) and standard physical treatment
Study: 11444885
Drug: Standard physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard physical treatment only
Study: 8111939
Drug: Decubitus position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decubitus position for 30 min after epidural blood patch
Study: 8111939
Drug: Decubitus position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decubitus position for 60 min after epidural blood patch
Study: 8111939
Drug: Decubitus position
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decubitus position for 120 min after epidural blood patch
Study: 3207854
Drug: ibuprofen SR
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen SR 800 mg
Study: 3207854
Drug: ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ranitidine 300 mg followed by ibuprofen SR 800 mg